Mass. hospital achieves EMRAM Stage 6

Milford Regional Medical Center in Milford, Mass., has been recognized by HIMSS Analytics for achieving Stage 6 on the Electronic Medical Records (EMR) Adoption Model (EMRAM).

Stage 6 hospitals

  • Have made significant executive commitments and investments to reach this stage.
  • Appear to have a significant advantage over competitors for patient safety, clinician support, clinician recruitment, and competitive marketing for both consumers and nurse recruitment. 
  • Have almost fully automated/paperless medical records when they have implemented their IT applications across most of the inpatient care settings.
  • Are either starting to evaluate their data for care delivery process improvements or have already documented significant improvements in this area.
  • Have made investments that are within reach of most hospitals and recognize the strategic value of improving patient care with the EMR.
  • Have begun to create strategic alignments with their medical staff to effectively utilize information technology to improve the patient safety environment
  • Are well positioned to provide data to key stakeholders, such as payers, the government, physicians, consumers, and employers, to support electronic health record environments and health information exchanges.

"It was a real team effort led by our IT department that allowed us to achieve Stage 6 on the EMR Adoption Model," said Milford Regional President Edward J. Kelly, in a release. "The fact that only 22 percent of hospitals nationwide have met this goal is a real testament to the commitment demonstrated by the Milford Regional team to pursue full implementation of this important advancement in healthcare technology."

  

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.